Margaret L. Fahnestock

This study identifies GPRC6A as a key regulator of mTORC1 signaling and tau pathology in tauopathies, showing that targeting GPRC6A could reduce tau accumulation and related neurodegeneration.

This study shows H2A.Z has opposite effects on memory and pathology in male and female Alzheimer's disease mice and patients, indicating sex-specific roles in disease progression.

This study shows that loss of RHBDL4 in Alzheimer's disease mice increases APP and rescues cognition by reducing proteasomal degradation of β-catenin.

This study shows that inhibiting H3K9me3 with ETP69 reduces AD pathology and improves cognition by modulating neuroinflammation and inducing Vgf.